Kazia Therapeutics (NASDAQ: KZIA)

Last close As at 01/04/2025

0.00 (0.00%)

Market capitalisation

Kazia Therapeutics is an ASX- and NASDAQ-listed biotechnology company. It is developing the PI3K/mTOR inhibitor GDC-0084 for brain cancer and Cantrixil for ovarian cancer. GDC-0084 was in-licensed from Genentech in 2016.

Latest Insights

View More

Thematics

thematic

Financials

UK equities: Not wrong to call them, but Europe surprised

thematic

TMT

MediaWatch – What now?

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free